Skip to content
Business Company News, Medical Health Aged Care

Servatus confirms the appointment of Mark Williams as CEO

Servatus Limited 2 mins read
Mark Williams, Servatus CEO

Servatus Limited, an Australian biopharmaceutical company delivering leading novel autoimmune and microbiome therapies, is pleased to announce the appointment of Mr Mark Williams as Chief Executive Officer.

First joining Servatus as a Non-Executive Director in February 2018, Mr Williams was appointed Chief Financial Officer and Executive Director in July 2018. Prior to joining Servatus, he had a long and successful career in investment banking, spending two decades with Macquarie Bank in senior roles in Sydney, London, and South America, ultimately leading Macquarie in Brazil. 

Mr Williams said he was deeply honoured to step into the CEO role at Servatus and build upon the legacy of Dr Wayne Finlayson, the Company’s Co-founder and CEO who passed away in September. “Wayne was a visionary and I am proud to build upon his ground-breaking work in microbiome-based therapeutics.” 

“Servatus is an exciting and dynamic business, with significant developments underway across our clinical program and our over-the-counter consumer products business, biomiq. We have several key inflection points over the coming 12 months that I’m confident will further cement our position as a leading microbiome-based therapeutics company globally.”

Servatus is progressing its comprehensive clinical program for its live biotherapeutics. Currently four clinical trials are in progress for insomnia, IBS-C, Helicobacter Pylori and Rheumatoid Arthritis, with a number of important data readouts expected in H1 2024.

Additionally, Servatus’ new biomiq skincare range expands Servatus’ biomiq product portfolio, which already includes a range of powdered OTC TGA-listed biotherapeutics that target specific health complaints, including constipation and bloating.

About us:

About Servatus |


Servatus Ltd is an unlisted public biopharmaceutical company focused on creating safe, effective, and reliable microbiome-based therapeutic drugs to treat several chronic and debilitating autoimmune diseases, as well as non-antibiotic treatments for bacterial infections.  


In addition to drug research and development, and ongoing clinical trials, Servatus also owns a state-of-the-art production facility. This facility means Servatus is able to oversee all aspects of the research development and production pipeline and ensure that its live microbial biotherapeutic drug candidates are made to the highest-standard and specifications, and removes the logistical uncertainty often associated with outsourcing manufacturing.

Contact details:


For further information please contact:

Jack McLintock

+61 450 608 022 


More from this category

  • Medical Health Aged Care
  • 20/04/2024
  • 04:30
Dementia Australia

Join us TODAY for Bendigo Memory Walk & Jog

What: Dementia Australia’sBendigoMemory Walk & Jog When: Saturday 20 April, from 8am Who: More than 390 locals participating on the day. People who have been impacted by dementia, their family, friends and carers. Where: Bendigo Botanic Gardens, Bendigo For more information visit: Walk or jog with us. We are in this together. Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people…

  • Contains:
  • Business Company News, Property Real Estate
  • 20/04/2024
  • 00:05

Legacy of Family Values Continues with Highland Expansion

Highland Property Group has today announced the expansion of the Highland brand into the Inner West with the merger with the Kallin family. The formation of Highland Inner West bridges the gap between the Eastern Suburbs and Highland Double Bay to the Sutherland Shire where Highland CEO and founder, David Highland first established the Highland brand, ensuring one holistic real estate offering throughout the greater Sydney area. A strong history between David Highland and Angela Kallin and her two daughters Jenna and Kristen, is the underpinning to this newest real estate merger, bringing the Highland/Kallin relationship full circle. From Mr…

  • Medical Health Aged Care, Science
  • 19/04/2024
  • 15:00
Monash University

Large-scale genetic study finds new link between Irritable Bowel Syndrome and the cardiovascular system

New research published today in the journal Cellular and Molecular Gastroenterology and Hepatology sheds light on disease mechanisms common to irritable bowel syndrome (IBS) and cardiovascular diseases (CVD). Led by Dr Leticia Camargo Tavares, a Postdoctoral Fellow at the Hypertension Research Laboratory within Monash University’s School of Biological Sciences, the study reveals novel insights into the genetic underpinnings of IBS, offering potential avenues for therapeutic intervention. IBS is one of the most prevalent gastrointestinal disorders globally, affecting up to 10 per cent of the population, with a disproportionate impact on women. It is characterised by a complex range of symptoms…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.